ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01957007
Recruitment Status : Completed
First Posted : October 8, 2013
Last Update Posted : July 27, 2017
Sponsor:
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 2016
  Actual Study Completion Date : June 2017